Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.

Paola RoaValentina FoglizzoGuilherme HaradaMatteo RepettoAmanda KulickElisa de StanchinaMichelle de MarchenaSupipi AuwardtShaza Sayed AhmedNicole Virginia BremerSoo-Ryum YangYangbo FengChao ZhouNorman KongRuixia LiangHaipeng XuBin ZhangAlberto Bardelli Eneda ToskaAndrea VenturaAlexander E Drilon Emiliano Cocco

Published in: British journal of cancer (2024)

Our data identifies zurletrectinib as a novel, highly potent next-generation TRK inhibitor with stronger in vivo brain penetration and intracranial activity than other next-generation agents.

Keyphrases

optic nerve
white matter
electronic health record
resting state
multiple sclerosis
machine learning
dna methylation
functional connectivity
cerebral ischemia
data analysis